TL;DR
- 1.The GHR Exon 3 deletion changes how efficiently your cells convert GH signals into IGF-1. D3 carriers run a receptor with stronger ERK signal amplification. About half the population has none of this advantage (fl/fl genotype).
- 2.The 2004 Nature Genetics study showed 1.7 to 2.0x growth acceleration in d3 carriers. A 2009 meta-analysis of 15 studies put the real-world effect at a more modest 0.52 cm per year extra. The community typically cites only the first number.
- 3.D3/d3 centenarians in longevity cohorts have LOWER serum IGF-1 than average yet live longer. Their receptor efficiency lets them achieve stronger downstream tissue signaling with less IGF-1 exposure.
- 4.No published RCT has tested d3-GHR genotype against GH secretagogue response (ipamorelin, CJC-1295, MK-677). The peptide community extrapolates from exogenous GH data. Mechanistically sound but not yet confirmed in a controlled trial.
- 5.If your growth peptide protocol is producing flat IGF-1, your GHR genotype is the first variable to investigate before changing dose, brand, or compound.
Your friend ran the same ipamorelin protocol you ran. Same dose, same timing, same compound. Their IGF-1 went up 90 ng/mL. Yours barely moved 15. Most people blame the peptide quality. The real answer is usually in one gene: the growth hormone receptor's exon 3 region, and whether you are carrying the deleted or full-length version.
Roughly half the population carries the full-length GHR (fl/fl) configuration and tends to see the weakest IGF-1 response per GH signal. This is the group for whom standard dosing charts were written but also the group they most consistently underserve.
The GHR Exon 3 deletion (d3-GHR) has been studied for over 20 years in growth hormone pharmacogenomics. It is the single best-documented structural variant predicting how efficiently the GH axis converts a peptide-stimulated GH pulse into downstream IGF-1. Yet almost no content aimed at peptide users mentions it by name. This article is the one that does.
Plain English: Your growth hormone receptor is the docking station where GH lands and starts a chain of signals that ends with your liver making IGF-1. The d3 variant is that same docking station with a more sensitive trigger. Same GH molecule arrives. Stronger downstream signal goes out. The fl/fl version is the factory default with lower sensitivity, requiring more GH pulses to reach the same IGF-1 output.
Does the GHR Exon 3 deletion actually show up in IGF-1 bloodwork?
In exogenous GH studies, yes. The evidence starts with a landmark 2004 paper in Nature Genetics by Dos Santos and colleagues, which followed 76 small-for-gestational-age children given standardized rhGH doses. D3 carriers showed 1.7 to 2.0 times more growth acceleration per unit of GH administered compared to fl/fl homozygotes (p<0.0001). That result launched over a decade of follow-up research across GH-deficient, Turner syndrome, and Prader-Willi cohorts.
"The d3-GHR allele was associated with a significantly greater first-year growth response to GH treatment, suggesting this polymorphism may be clinically useful as a pharmacogenomic predictor of GH responsiveness."
Dos Santos et al., Nature Genetics, 2004
But the follow-up research introduced an important correction the community rarely repeats. A 2009 meta-analysis by Wassenaar et al. published in the Journal of Clinical Endocrinology and Metabolism pooled 15 studies and found the real-world effect was much smaller: an additional 0.52 cm per year in height velocity (95% CI: 0.20 to 1.02 cm). Meaningful, but nowhere near the 1.7x headline from the original cohort. This is what usually happens when a striking small-study result meets a systematic review with 15 times the sample size.
The mechanism received a more precise answer in a 2023 review by Falah, Sharvit, and Atzmon published in the International Journal of Molecular Sciences. The key clarification: STAT5B phosphorylation does not actually differ between the d3 and fl isoforms. What does differ is the ERK arm of GH signaling. D3 carriers show lower basal ERK activation but a markedly stronger ERK response when GH arrives. Think of it as a hair-trigger pattern: quieter at baseline, bigger burst when stimulated.
Population distribution: this affects most people you know
The d3-GHR deletion is not a rare variant. In European ancestry populations, the three genotypes distribute roughly as follows across most study populations:
| Genotype | Frequency | Signal Pattern | Practical Implication |
|---|---|---|---|
| fl/fl (no deletion) | ~50% | Lowest baseline sensitivity | Weakest IGF-1 per GH pulse; benefits more from pulse frequency than dose size |
| fl/d3 (one deletion) | ~30-40% | Moderate advantage | Responds well at standard doses; intermediate bloodwork outcomes |
| d3/d3 (two deletions) | ~10-20% | Strongest ERK amplification | Most likely to over-respond at standard doses; early bloodwork check is mandatory |
Why d3/d3 centenarians have lower IGF-1 than average: what it means for your protocol
Here is the finding that should make you reconsider what IGF-1 bloodwork actually tells you.
Ben-Avraham and colleagues published a 2017 study in Science Advances analyzing 841 participants across four longevity cohorts including Ashkenazi Jewish centenarian populations. D3/d3 homozygous males were approximately one inch taller than fl/fl controls. In the centenarian subgroup, d3/d3 homozygosity appeared at roughly three times the rate of younger controls (12% vs. 4%), and d3 allele prevalence increased significantly with advancing age across cohorts.
D3/d3 homozygosity appeared roughly three times as often in Ashkenazi Jewish centenarians compared to younger controls (12% vs. 4%) in the Ben-Avraham 2017 longevity study published in Science Advances. The variant associated with stronger GH signaling is enriched in the people who live longest.
Here is what does not fit the standard story: those same d3/d3 centenarians had lower serum IGF-1 than average (p=0.003). Not higher. Lower. Yet their lymphocytes showed superior ERK activation in response to GH stimulation. The receptor was more responsive to each GH signal. The blood IGF-1 number was smaller.
The implication for peptide users is significant. The community standard is to raise IGF-1 as high as possible within a healthy adult range, typically cited as 200 to 350 ng/mL for people on GH protocols. But d3/d3 carriers appear to achieve equivalent or superior downstream tissue signaling with less circulating IGF-1. If you are a d3/d3 user chasing a higher IGF-1 number and feeling like your results do not match your labs, this is the most likely explanation. Your blood level is an underestimate of what your tissues are actually receiving.
The honest answer about ipamorelin and CJC-1295: what we know and what we do not
This is where the community often oversimplifies.
No published randomized trial has tested d3-GHR genotype against GH secretagogue response. Not for ipamorelin. Not for CJC-1295. Not for MK-677. Every study that established the d3 advantage used injected recombinant GH, not peptides that stimulate pituitary GH release. These are different mechanisms at the upstream step of the same cascade.
The reasonable extrapolation works like this. Ipamorelin acts on GHSR-1a receptors in the pituitary to trigger GH release. CJC-1295 binds GHRH receptors to amplify GH pulse amplitude. The GH that gets released is the same molecule regardless of what triggered it. When that GH then binds growth hormone receptors in peripheral tissue, the d3 efficiency advantage should apply the same way it applies to injected somatropin. Your liver does not know whether the GH came from a peptide injection, a direct rhGH injection, or a natural sleep-driven pulse. But this is mechanistic reasoning, not measured data from a secretagogue trial. You should factor in both the plausibility and the uncertainty when designing your protocol.
Protocol for fl/fl users
You are running the least sensitive GHR configuration. Twice-daily ipamorelin dosing typically outperforms single larger doses because you need more GH pulses to overcome the lower per-pulse receptor efficiency. Chasing a higher single dose produces diminishing returns for fl/fl. Track IGF-1 at standard doses for 8 weeks before escalating dose size, and escalate frequency first.
Protocol for d3/d3 users
Standard dosing protocols were not designed with your receptor sensitivity in mind. At 200 mcg ipamorelin twice daily, you may push IGF-1 significantly higher than the protocol intended, and your blood level will still underestimate your tissue exposure per the longevity data. Start at the lower end of dosing ranges. Get bloodwork at week 4 before adjusting upward.
GHR genotype and GHSR variants are different problems at different steps
GHR Exon 3 and GHSR are two separate genes at two different points in the same chain. GHSR (ghrelin receptor) is where ipamorelin and GHRP-6 bind to trigger GH release from the pituitary. GHR is where that released GH then lands in peripheral tissue to start producing IGF-1. They are upstream and downstream in the same cascade, not interchangeable.
A GHSR loss-of-function variant blocks the first step. No amount of d3-GHR efficiency downstream can compensate for GH that was never released. This is why some users get zero IGF-1 improvement on ipamorelin despite having a favorable GHR genotype. The bottleneck is upstream and invisible to the receptor. For a full breakdown of how to distinguish a GHSR bottleneck from a GHR efficiency gap, see our companion article on IGF-1 receptor genetics and growth peptide response, which covers the practical diagnostic protocol in detail.
The fastest practical screen is this: run a baseline IGF-1, complete a standard 8-week protocol, and test again. A response below 20 ng/mL on adequate ipamorelin doses typically points toward a GHSR problem. A response above 60 ng/mL suggests d3 carrier status or better. A flat result that improves when switching from ipamorelin to CJC-1295 alone is a GHSR signal. See ipamorelin vs CJC-1295 for how to run this distinction. For how long to wait between cycles before retesting, the GH receptor reset timeline article has the week-by-week recovery data.
How do you find out your GHR Exon 3 genotype?
The d3-GHR status is not included in most standard consumer genetic panels. Most 23andMe or AncestryDNA results do not genotype the exon 3 structural deletion directly. A few practical paths exist.
Functional bloodwork testing: Run a baseline IGF-1 before starting any growth peptide protocol. After 8 weeks on standard ipamorelin or CJC-1295 plus ipamorelin dosing, test again. High responders above 60 to 80 ng/mL increase at standard doses are consistent with d3 carrier status. Flat response below 20 ng/mL points toward either fl/fl or a GHSR bottleneck. This does not give you a genotype, but it tells you the thing that matters: how your axis responds in practice at this dose.
Direct genotyping through PeptidesDNA: The PeptidesDNA report analyzes GHR Exon 3 status when you upload raw genetic data at our upload page or order a saliva kit. Whole-genome sequencing services that return raw data files can also be analyzed for this structural variant, though interpretation requires specialized structural variant calling tools.
Specialist pharmacogenomics labs: A growing number of US and European labs now offer targeted GHR d3 genotyping on request, typically alongside a broader CYP panel. Coverage varies and most clinicians do not order it routinely as part of standard care.
For most users starting a growth peptide protocol, functional bloodwork testing is the fastest and most actionable first step. Knowing your genotype refines protocol expectations, but direct measurement of how your axis responds in practice is always more informative than the genotype alone.
Verdict: The GHR Exon 3 deletion is the most studied single structural variant in growth hormone pharmacogenomics, with over two decades of clinical data. It affects roughly half the population and predicts receptor-level signal efficiency in exogenous GH studies with a real but modest effect size (about 0.52 cm per year extra in the largest meta-analysis, not the 2x often cited). For secretagogues specifically, the connection is mechanistically grounded but empirically unproven. If your growth peptide protocol is underperforming on bloodwork, GHR genotype is the first place to look, followed by GHSR status. If your IGF-1 is rising faster than expected, you may be a d3 carrier whose tissue response exceeds what the blood number shows. Upload your data at PeptidesDNA or order a kit to find out where your receptor efficiency actually sits before adjusting protocol.
Your DNA shapes how you respond to every peptide in this report.
A personalized report scores 25+ peptides against your unique genetic profile — including the ones covered in this article.
Frequently asked questions
What is the GHR Exon 3 deletion and how common is it?
The GHR Exon 3 deletion (d3-GHR) removes 22 amino acids from the extracellular domain of the growth hormone receptor, producing a more sensitive ERK signaling response when GH binds. About 40 to 50% of people carry at least one d3 allele (fl/d3 heterozygous), and roughly 10 to 20% carry two copies (d3/d3 homozygous). About half the population carries none and runs the baseline fl/fl configuration.
Does my GHR genotype affect ipamorelin or CJC-1295 results?
Mechanistically, yes. The d3-GHR amplifies ERK signaling in response to any GH molecule regardless of what triggered its release. However, no randomized trial has directly tested d3-GHR genotype against secretagogue response. Every study establishing the d3 advantage used injected somatropin. The extrapolation to peptides is scientifically reasonable but not yet confirmed in a controlled trial.
How do I find out if I have the GHR Exon 3 deletion?
Most consumer panels (23andMe, AncestryDNA) do not genotype this structural deletion directly. The fastest practical screen is a baseline IGF-1 test, followed by 8 weeks on standard ipamorelin or CJC-1295, then a follow-up test. High responders above 60 ng/mL increase at standard doses suggest d3 carrier status. PeptidesDNA includes GHR Exon 3 analysis when raw genetic data is uploaded or a saliva kit is ordered.
If I am fl/fl, should I take a higher ipamorelin dose?
Higher dose escalation alone typically produces diminishing returns for fl/fl users. A higher pulse frequency (twice daily instead of once) tends to outperform single larger doses because the fl/fl receptor is less sensitive per pulse, not more resistant to total daily stimulation. Run bloodwork on a standard dose for 8 weeks before assuming you need to go higher on dose size.
Why do d3/d3 centenarians have lower IGF-1 if the variant is beneficial?
Ben-Avraham et al. 2017 found that d3/d3 centenarians in Ashkenazi Jewish longevity cohorts showed superior ERK activation in lymphocytes when GH arrived, despite lower average serum IGF-1. The interpretation is that d3-GHR delivers more efficient downstream tissue signaling with less circulating IGF-1. Standard IGF-1 blood levels likely underestimate the actual anabolic signal in d3 carriers, which means chasing a high IGF-1 number is less important for this genotype.
Can the GHR Exon 3 genotype explain why my peptides worked and then stopped?
Unlikely on its own. GHR Exon 3 genotype is a fixed structural variant that does not change over time. If your response dropped after an initial period of working well, receptor desensitization or protocol cycling are more likely explanations. Your genotype sets the ceiling and sensitivity level, but cycle length and receptor recovery govern the time course of response. Our article on GH receptor reset timelines covers the recovery data.
This article is for informational and educational purposes only. It is not medical advice and does not diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before starting any peptide protocol. Individual results vary.